Literature DB >> 8260877

Characterization of the endogenous protein kinase activity of the hepatitis B virus.

M Kann1, R Thomssen, H G Köchel, W H Gerlich.   

Abstract

During the assembly of the nucleocapsid of the hepatitis B virus a protein kinase, probably of cellular origin, is encapsidated. This enzyme phosphorylates serine residue(s) localized within the lumen of the particle. By using purified, liver-derived core particles, we characterized the protein kinase activity in the presence of different ions and inhibitors. Controls were performed with cAMP-dependent protein kinase (PKA) and protein kinase C (PKC) and recombinant core particles. We showed that the endogenous protein kinase of the core particles was not inhibited by H89, a specific inhibitor of PKA. Staurosporine, a selective inhibitor of PKC inhibited the endogenous kinase activity only within the first minutes of the reaction. In contrast, quercetine, a selective inhibitor of the protein kinase M (PKM) did not inhibit during the first minutes but inhibited efficiently during later phases of incubation. PKM represents an enzymatically active proteolytic fragment of PKC. These results suggest that PKC is encapsidated into human core particles and is converted to PKM during the in vitro reaction. This conclusion implies the association of a protease activity localized with the HBV nucleocapsid inside liver-derived core particles.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8260877     DOI: 10.1007/978-3-7091-9312-9_6

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  13 in total

1.  Hepatitis B virus core gene mutations which block nucleocapsid envelopment.

Authors:  M Koschel; D Oed; T Gerelsaikhan; R Thomssen; V Bruss
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Phosphorylation of the core protein of hepatitis B virus by a 46-kilodalton serine kinase.

Authors:  J H Kau; L P Ting
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  In vitro model for the nuclear transport of the hepadnavirus genome.

Authors:  M Kann; A Bischof; W H Gerlich
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

4.  The large surface protein of duck hepatitis B virus is phosphorylated in the pre-S domain.

Authors:  E V Grgacic; D A Anderson
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

Review 5.  Core protein: A pleiotropic keystone in the HBV lifecycle.

Authors:  Adam Zlotnick; Balasubramanian Venkatakrishnan; Zhenning Tan; Eric Lewellyn; William Turner; Samson Francis
Journal:  Antiviral Res       Date:  2015-06-27       Impact factor: 5.970

6.  Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus.

Authors:  M Kann; W H Gerlich
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein.

Authors:  Henrik Daub; Stephanie Blencke; Peter Habenberger; Alexander Kurtenbach; Julia Dennenmoser; Josef Wissing; Axel Ullrich; Matt Cotten
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity.

Authors:  Michelle J Farquhar; Helen J Harris; Mandy Diskar; Sarah Jones; Christopher J Mee; Søren U Nielsen; Claire L Brimacombe; Sonia Molina; Geoffrey L Toms; Patrick Maurel; John Howl; Friedrich W Herberg; Sven C D van Ijzendoorn; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  Cyclin-dependent kinase 2 phosphorylates s/t-p sites in the hepadnavirus core protein C-terminal domain and is incorporated into viral capsids.

Authors:  Laurie Ludgate; Xiaojun Ning; David H Nguyen; Christina Adams; Laura Mentzer; Jianming Hu
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

10.  HBV life cycle: entry and morphogenesis.

Authors:  Stephanie Schädler; Eberhard Hildt
Journal:  Viruses       Date:  2009-09-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.